[English] 日本語

- EMDB-7860: HIV-1 Envelope Glycoprotein clone PC64M18C043.SOSIP.664 complex w... -
+
Open data
-
Basic information
Entry | Database: EMDB / ID: EMD-7860 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Title | HIV-1 Envelope Glycoprotein clone PC64M18C043.SOSIP.664 complex with PGT151 Fab | |||||||||
![]() | HIV-1 Envelope Glycoprotein clone PC64M18C043.SOSIP.664 complex with PGT151 Fab, full map | |||||||||
![]() |
| |||||||||
Biological species | ![]() ![]() ![]() | |||||||||
Method | single particle reconstruction / cryo EM / Resolution: 4.9 Å | |||||||||
![]() | Berndsens ZB / Rantalainen KR / Ward AB | |||||||||
![]() | ![]() Title: Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design. Authors: Kimmo Rantalainen / Zachary T Berndsen / Sasha Murrell / Liwei Cao / Oluwarotimi Omorodion / Jonathan L Torres / Mengyu Wu / Jeffrey Umotoy / Jeffrey Copps / Pascal Poignard / Elise Landais ...Authors: Kimmo Rantalainen / Zachary T Berndsen / Sasha Murrell / Liwei Cao / Oluwarotimi Omorodion / Jonathan L Torres / Mengyu Wu / Jeffrey Umotoy / Jeffrey Copps / Pascal Poignard / Elise Landais / James C Paulson / Ian A Wilson / Andrew B Ward / ![]() Abstract: Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typically take years to develop. Longitudinal analyses of both neutralizing antibody lineages and viruses at ...Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typically take years to develop. Longitudinal analyses of both neutralizing antibody lineages and viruses at serial time points during infection provide a basis for understanding the co-evolutionary contest between HIV and the humoral immune system. Here, we describe the structural characterization of an apex-targeting antibody lineage and autologous clade A viral Env from a donor in the Protocol C cohort. Comparison of Ab-Env complexes at early and late time points reveals that, within the antibody lineage, the CDRH3 loop rigidifies, the bnAb angle of approach steepens, and surface charges are mutated to accommodate glycan changes. Additionally, we observed differences in site-specific glycosylation between soluble and full-length Env constructs, which may be important for tuning optimal immunogenicity in soluble Env trimers. These studies therefore provide important guideposts for design of immunogens that prime and mature nAb responses to the Env V2-apex. | |||||||||
History |
|
-
Structure visualization
Movie |
![]() |
---|---|
Structure viewer | EM map: ![]() ![]() ![]() |
Supplemental images |
-
Downloads & links
-EMDB archive
Map data | ![]() | 116.8 MB | ![]() | |
---|---|---|---|---|
Header (meta data) | ![]() ![]() | 18.2 KB 18.2 KB | Display Display | ![]() |
FSC (resolution estimation) | ![]() | 11.5 KB | Display | ![]() |
Images | ![]() | 98 KB | ||
Masks | ![]() | 125 MB | ![]() | |
Others | ![]() ![]() | 98.3 MB 98.3 MB | ||
Archive directory | ![]() ![]() | HTTPS FTP |
-Related structure data
Related structure data | ![]() 7858C ![]() 7859C ![]() 7861C ![]() 7862C ![]() 7863C ![]() 7864C ![]() 7865C ![]() 7866C ![]() 6ca6C ![]() 6ca7C ![]() 6ca9C ![]() 6dcqC C: citing same article ( |
---|---|
Similar structure data |
-
Links
EMDB pages | ![]() ![]() |
---|
-
Map
File | ![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | HIV-1 Envelope Glycoprotein clone PC64M18C043.SOSIP.664 complex with PGT151 Fab, full map | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Projections & slices | Image control
Images are generated by Spider. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Voxel size | X=Y=Z: 1.03 Å | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Density |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Symmetry | Space group: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Details | EMDB XML:
CCP4 map header:
|
-Supplemental data
-Mask #1
File | ![]() | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Projections & Slices |
| ||||||||||||
Density Histograms |
-Half map: HIV-1 Envelope Glycoprotein clone PC64M18C043.SOSIP.664 complex with PGT151...
File | emd_7860_half_map_1.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | HIV-1 Envelope Glycoprotein clone PC64M18C043.SOSIP.664 complex with PGT151 Fab, half map 1 | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-Half map: HIV-1 Envelope Glycoprotein clone PC64M18C043.SOSIP.664 complex with PGT151...
File | emd_7860_half_map_2.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | HIV-1 Envelope Glycoprotein clone PC64M18C043.SOSIP.664 complex with PGT151 Fab, half map 2 | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-
Sample components
-Entire : HIV-1 Envelope glycoprotein clone PC64M18C043.SOSIP.664 in comple...
Entire | Name: HIV-1 Envelope glycoprotein clone PC64M18C043.SOSIP.664 in complex with PGT151 Fab |
---|---|
Components |
|
-Supramolecule #1: HIV-1 Envelope glycoprotein clone PC64M18C043.SOSIP.664 in comple...
Supramolecule | Name: HIV-1 Envelope glycoprotein clone PC64M18C043.SOSIP.664 in complex with PGT151 Fab type: complex / ID: 1 / Parent: 0 / Macromolecule list: all |
---|---|
Source (natural) | Organism: ![]() ![]() |
-Macromolecule #1: HIV-1 Envelope Glycoprotein clone PC64M18C043.SOSIP.664
Macromolecule | Name: HIV-1 Envelope Glycoprotein clone PC64M18C043.SOSIP.664 type: protein_or_peptide / ID: 1 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: ![]() ![]() |
Recombinant expression | Organism: ![]() |
Sequence | String: MDAMKRGLCC VLLLCGAVFV SPSQEIHARF RRGARAANNL WVTVYYGVPV WRDAETTLFC ASDAKAYDTE VHNVWATHAC VPTDPSPQEI HLANVTEKFD MWKNSMVEQM HTDIISLWDE SLKPCVKLTP LCITLNCTNI TRNVTGGNLT EEGKEELKNC SFNATTELRD ...String: MDAMKRGLCC VLLLCGAVFV SPSQEIHARF RRGARAANNL WVTVYYGVPV WRDAETTLFC ASDAKAYDTE VHNVWATHAC VPTDPSPQEI HLANVTEKFD MWKNSMVEQM HTDIISLWDE SLKPCVKLTP LCITLNCTNI TRNVTGGNLT EEGKEELKNC SFNATTELRD KIQKVHSLFY RLDLVELNEG NSSDSNTSMY RLINCNTSAI TQACPKVSFE PIPIHYCAPA GFAILKCREK EFNGTGPCKK VSTVQCTHGI KPVVSTQLLL NGSLAEGKVK IRCENISNNA KTILVQLTTP VRINCTRPSN NTRTSIRIGP GQSFYATGDI IGDIRKAYCN VSESEWKEAL GKVVEQLRNH FNKTITFASS SGGDLEITTH SFNCGGEFFY CNTSSLFNST WDGNSATNST QVPNGTITLP CRIKQIINMW QRTGQAMYAP PIPGKIRCDS NITGLILIRD GGNNNNESET FRPGGGDMRN NWRSELYKYK VVKIDPLGVA PTGCKRRVVE RRRRRRAVGI GAVLFGFLGA AGSTMGAASL TLTVQARQLL SGIVQQQSNL LRAPEAQQHL LRLTVWGIKQ LQARVLAVER YLSDQQLLGI WGCSGKLICC TNVPWNSSWS NKSQDEIWNN MTWLQWDKEI SNYTDTIYYL IEKSQNQQEV NEKDLLALD |
-Macromolecule #2: Immunoglobulin G PGT151 Fab, Heavy chain
Macromolecule | Name: Immunoglobulin G PGT151 Fab, Heavy chain / type: protein_or_peptide / ID: 2 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: ![]() |
Recombinant expression | Organism: ![]() |
Sequence | String: RVQLVESGGG VVQPGKSVRL SCVVSDFPFS KYPMYWVRQA PGKGLEWVAA ISGDAWHVVY SNSVQGRFLV SRDNVKNTLY LEMNSLKIE DTAVYRCARM FQESGPPRLD RWSGRNYYYY SGMDVWGQGT TVTVSSASTK GPSVFPLAPS SKSTSGGTAA L GCLVKDYF ...String: RVQLVESGGG VVQPGKSVRL SCVVSDFPFS KYPMYWVRQA PGKGLEWVAA ISGDAWHVVY SNSVQGRFLV SRDNVKNTLY LEMNSLKIE DTAVYRCARM FQESGPPRLD RWSGRNYYYY SGMDVWGQGT TVTVSSASTK GPSVFPLAPS SKSTSGGTAA L GCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DK |
-Macromolecule #3: Immunoglobulin G PGT151, Light chain
Macromolecule | Name: Immunoglobulin G PGT151, Light chain / type: protein_or_peptide / ID: 3 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: ![]() |
Recombinant expression | Organism: ![]() |
Sequence | String: DIVMTQTPLS LSVTPGQPAS ISCKSSESLR QSNGKTSLYW YRQKPGQSPQ LLVFEVSNRF SGVSDRFVGS GSGTDFTLRI SRVEAEDVG FYYCMQSKDF PLTFGGGTKV DLKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA KVQWKVDNAL Q SGNSQESV ...String: DIVMTQTPLS LSVTPGQPAS ISCKSSESLR QSNGKTSLYW YRQKPGQSPQ LLVFEVSNRF SGVSDRFVGS GSGTDFTLRI SRVEAEDVG FYYCMQSKDF PLTFGGGTKV DLKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA KVQWKVDNAL Q SGNSQESV TEQDSKDSTY SLSSTLTLSK ADYEKHKVYA CEVTHQGLSS PVTKSFNRGE C |
-Experimental details
-Structure determination
Method | cryo EM |
---|---|
![]() | single particle reconstruction |
Aggregation state | particle |
-
Sample preparation
Concentration | 7 mg/mL |
---|---|
Buffer | pH: 7.4 Details: Detergent removed with Biobeads prior to grid freezing |
Grid | Model: C-flat-2/2 / Material: COPPER / Mesh: 400 / Support film - Material: CARBON / Support film - topology: HOLEY |
Vitrification | Cryogen name: ETHANE / Chamber humidity: 100 % / Chamber temperature: 277.15 K / Instrument: FEI VITROBOT MARK IV |
-
Electron microscopy
Microscope | FEI TITAN KRIOS |
---|---|
Image recording | Film or detector model: GATAN K2 SUMMIT (4k x 4k) / Detector mode: COUNTING / Number real images: 1555 / Average electron dose: 81.1 e/Å2 |
Electron beam | Acceleration voltage: 300 kV / Electron source: ![]() |
Electron optics | C2 aperture diameter: 100.0 µm / Illumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD / Cs: 2.7 mm |
Experimental equipment | ![]() Model: Titan Krios / Image courtesy: FEI Company |